Patents by Inventor Steven Boakes
Steven Boakes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230340026Abstract: The present invention provides a compound of formula (I), and its use in methods of treatment, including the treatment of bacterial infections. Methods for the preparation of the compound of formula (I) are also provided.Type: ApplicationFiled: April 25, 2023Publication date: October 26, 2023Inventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy, Steven James Stanway, Antoinette Wilson, Stephen Frederick Moss
-
Publication number: 20230322858Abstract: Provided are compounds of formula (III), and the use of compounds of formula (III) in methods of treatment, such as methods of treating a microbial infection. The compounds of formula (III) is: where —R15 is an amino-containing group: and —R1, —R2, —R3, —R4, —R8, —RA, Q, —R16, —R17 are as described in further detail in the description.Type: ApplicationFiled: March 24, 2023Publication date: October 12, 2023Inventors: Pamela BROWN, Michael DAWSON, Mona SIMONOVIC, Steven BOAKES, Esther DUPERCHY, Steven James STANWAY, Antoinette WILSON, Stephen Frederick MOSS
-
Publication number: 20230012121Abstract: The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: wherein —R15 is a group: and —R16 is hydrogen; —R17 is hydrogen; -L- is a covalent bond or methylene; and —Ar is optionally substituted aryl. The groups —X—, —R1, —R2, —R3, —R4, and —R8 are as defined herein.Type: ApplicationFiled: August 23, 2022Publication date: January 12, 2023Inventors: Pamela BROWN, Michael DAWSON, Mona SIMONOVIC, Steven BOAKES, Esther DUPERCHY, Dean RIVERS, Roy LESTER, Scott COLEMAN
-
Patent number: 11459357Abstract: The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: wherein —R15 is a group: and —R16 is hydrogen; —R17 is hydrogen -L- is a covalent bond or methylene; and —Ar is optionally substituted aryl. The groups —X—, —R1, —R2, —R3, —R4, and —R8 are as defined herein.Type: GrantFiled: June 25, 2019Date of Patent: October 4, 2022Assignee: SPERO THERAPEUTICS, INC.Inventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy, Dean Rivers, Roy Lester, Scott Coleman
-
Publication number: 20210246169Abstract: The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus: wherein —R15 is a group: and —R16 is hydrogen; —R17 is hydrogen -L- is a covalent bond or methylene; and —Ar is optionally substituted aryl. The groups —X—, —R1, —R2, —R3, —R4, and —R8 are as defined herein.Type: ApplicationFiled: June 25, 2019Publication date: August 12, 2021Applicant: Spero Therapeutics, Inc.Inventors: Pamela BROWN, Michael DAWSON, Mona SIMONOVIC, Steven BOAKES, Esther DUPERCHY, Dean RIVERS, Roy LESTER, Scott COLEMAN
-
Publication number: 20210221848Abstract: Provided are compounds of formula (III), and the use of compounds of formula (III) in methods of treatment, such as methods of treating a microbial infection. The compounds of formula (III) is: where —R15 is an amino-containing group: and —R1, —R2, —R3, —R4, —R, —RA, Q, —R16, —R17 are as described in further detail in the description.Type: ApplicationFiled: January 25, 2021Publication date: July 22, 2021Inventors: Pamela BROWN, Michael DAWSON, Mona SIMONOVIC, Steven BOAKES, Esther DUPERCHY, Steven James STANWAY, Antoinette WILSON, Stephen Frederick MOSS
-
Patent number: 10407467Abstract: Described are compounds of formula (I) for use in combination treatment with a second active agent, such as rifampicin, for example for treatment of a microbial infection. The compound of formula (I) is a polymyxin compound is: where the groups -A-, —R1, —R2, —R3, —R4, —R5, —R6, —R7, —R8, and —X— are described in detail within the description.Type: GrantFiled: May 21, 2014Date of Patent: September 10, 2019Assignee: NEW PHARMA LICENCE HOLDINGS LIMITEDInventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy
-
Publication number: 20180030092Abstract: The present invention provides a compound of formula (I), and its use in methods of treatment, including the treatment of bacterial infections. Methods for the preparation of the compound of formula (I) are also provided.Type: ApplicationFiled: November 26, 2015Publication date: February 1, 2018Inventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy, Steven James Stanway, Antoinette Wilson, Stephen Frederick Moss
-
Publication number: 20170073373Abstract: Provided are compounds of formula (III), and the use of compounds of formula (III) in methods of treatment, such as methods of treating a microbial infection. The compounds of formula (III) is: where —R15 is an amino-containing group: and —R1, —R2, —R3, —R4, —R8, —RA, Q, —R16, —R17 are as described in further detail in the description.Type: ApplicationFiled: March 11, 2015Publication date: March 16, 2017Inventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy, Steven James Stanway, Antoinette Wilson, Stephen Frederick Moss
-
Publication number: 20160222061Abstract: Described are compounds of formula (I) for use in combination treatment with a second active agent, such as rifampicin, for example for treatment of a microbial infection. The compound of formula (I) is a polymyxin compound is: where the groups -A-, —R1, —R2, —R3, —R4, —R5, —R6, —R7, —R8, and —X— are described in detail within the description.Type: ApplicationFiled: May 21, 2014Publication date: August 4, 2016Applicant: NEW PHARMA LICENCE HOLDINGS LIMITEDInventors: Pamela Brown, Michael Dawson, Mona Simonovic, Steven Boakes, Esther Duperchy
-
Patent number: 8465947Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic antibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterized biosynthetic gene clusters, is described.Type: GrantFiled: June 10, 2011Date of Patent: June 18, 2013Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Publication number: 20110306091Abstract: This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterised biosynthetic gene clusters.Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Applicant: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Patent number: 7989416Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.Type: GrantFiled: January 17, 2007Date of Patent: August 2, 2011Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Publication number: 20100048459Abstract: This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced according to this invention, utilizing genes from the characterised biosynthetic gene clusters.Type: ApplicationFiled: January 17, 2007Publication date: February 25, 2010Inventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson
-
Patent number: 7592308Abstract: The present invention relates to methods and products for improved production of the lantibiotic mersacidin. There is provided a method of producing a mersacidin variant which comprises introducing into a cell which is a ?MrsA host cell an expression vector encoding said variant, and recovering said variant from the cell culture. Preferred variants include the novel variants of Table 1, e.g. mersacidin F3W, said mersacidin F3W optionally having a further one or more variations, e.g. mersacidin F3W G8A. Also provided is a Bacillus cell which is a SigH deficient strain of Bacillus sp. HIL Y-85,54728 (NCIMB Accession Number NCIMB 41211); this cell may also be used in the production of mersacidin and its variants. Further aspects of the invention include a DNA cassette which comprises a nucleotide sequence encoding the mersacidin mrsA propeptide, and a method to transform a Bacillus HIL host cell with plasmid, which method includes the step of electroporation.Type: GrantFiled: September 25, 2006Date of Patent: September 22, 2009Assignee: Novacta Biosystems LimitedInventors: Michael John Dawson, Jesus Cortes Bargallo, Antony Nicholas Appleyard, Brian Arthur Michael Rudd, Steven Boakes, Gabriele Bierbaum, Anja Hoffmann, Stephanie Schmitz
-
Publication number: 20070117749Abstract: The present invention relates to methods and products for improved production of the lantibiotic mersacidin. There is provided a method of producing a mersacidin variant which comprises introducing into a cell which is a ?MrsA host cell an expression vector encoding said variant, and recovering said variant from the cell culture. Preferred variants include the novel variants of Table 1, e.g. mersacidin F3W, said mersacidin F3W optionally having a further one or more variations, e.g. mersacidin F3W G8A. Also provided is a Bacillus cell which is a SigH deficient strain of Bacillus sp. HIL Y-85,54728 (NCIMB Accession Number NCIMB 41211); this cell may also be used in the production of mersacidin and its variants. Further aspects of the invention include a DNA cassette which comprises a nucleotide sequence encoding the mersacidin mrsA propeptide, and a method to transform a Bacillus HIL host cell with plasmid, which method includes the step of electroporation.Type: ApplicationFiled: September 25, 2006Publication date: May 24, 2007Applicant: Novacta Biosystems LimitedInventors: Michael Dawson, Jesus Cortes Bargallo, Antony Appleyard, Brian Rudd, Steven Boakes, Gabriele Bierbaum, Anja Hoffmann, Stephanie Schmitz
-
Patent number: RE45003Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.Type: GrantFiled: December 4, 2012Date of Patent: July 8, 2014Assignee: Novacta Biosystems LimitedInventors: Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson